Antimicrobial Effect of Piceatannol, a Resveratrol Metabolite, on Staphylococcus Aureus

Year 2019, Volume: 3 Issue: 3, 184 - 187, 01.09.2019

Nevcivan Güldaş Tuğba Uysal Hülya Ellidokuz Yasemin Başbınar

https://doi.org/10.30621/jbachs.2019.745

Cited By: 1

Abstract

Objectives: Staphylococcus aureus S. aureus is one of the major human pathogens in both community acquired and nosocomial infections. Heavy increase of antibiotic resistance between S. aureus strains became an important public health problem in progress of time. In this study, the antimicrobial effects of piceatannol on S. aureus growth was investigated.Patients and Methods: The antimicrobial effect of piceatannol on a standard S. aureus DSMZ 6148 strain and two clinical S. aureus strains C1 and C2 was tested in vitro at concentrations between 0 and 750 µg/ mL. Tigecycline and gentamicin were used as positive controls. For each strain, the minimum inhibitory concentration MIC and the minimum bactericidal concentration MBC values of piceatannol and the control antibiotics were determined separately using the broth microdilution method according to CLSI Clinical and Laboratory Standards Institute standards at 24 and 48 h.Results: After 24 and 48 h of treatment with piceatannol, the average MIC for all tested strains was 283 µg/mL and 383 µg/mL, respectively. Bactericidal activity increased as piceatannol concentration increased for one of the three strains. After 24 and 48 h of treatment with piceatannol, the average MBC for all strains was 717 µg/ mL and 583 µg/ mL, respectively. The S. aureus strains were found to be susceptible to tigecycline and gentamicin.Conclusion: Piceatannol has antimicrobial effect against S. aureus; however, more data regarding the effects of this compound on other microorganisms and its bioavailability are needed

Keywords

Piceatannol, Staphylococcus aureus, antimicrobial effect

References

• Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015;28:603–661. [CrossRef]
• Randrianirina F, Soares JL, Ratsima E, et al. In vitro activities of 18 antimicrobial agents against Staphylococcus aureus isolates from the Institut Pasteur of Madagascar. Ann Clin Microbiol Antimicrob 2007;6:5. [CrossRef]
• Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 2005;11:33–42. [CrossRef]
• Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin- resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26;43–49. [CrossRef]
• Drees M, Boucher H. New agents for Staphylococcus aureus endocarditis. Curr Opin Infect Dis 2006;19:544–550. [CrossRef]
• Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007;45:S184–S190. [CrossRef]
• Bakthavatchalam YD, Ramaswamy B, Janakiraman R, Steve RJ, Veeraraghavan B. Genomic insights of reduced teicoplanin susceptible community acquired methicillin resistant Staphylococcus aureus MRSA. Case of necrotizing fasciitis. J Glob Antimicrob Resist 2018;14:242–245. [CrossRef]
• Paulo L, Oleastro M, Gallardo E, Queiroz JA, Domingues F. Antimicrobial properties of resveratrol: a review. In: Méndez-Vilas A, editor. Science against microbial pathogens: communicating current research and technological advances, Volume 2, 1st ed. Badajoz, Spain: Formatex; 2011. pp 1225–1235.
• Docherty JJ, McEwen HA, Sweet TJ, Bailey E, Booth TD. Resveratrol inhibition of Propionibacterium acnes. J Antimicrob Chemother 2007;59:1182–1184. [CrossRef]
• Taylor EJM, Yu Y, Champer J, Kim J. Resveratrol Demonstrates Antimicrobial Effects Against Propionibacterium acnes In Vitro. Dermatol Ther (Heidelb) 2014;4:249–257. [CrossRef]
• Mahady GB, Pendland SL. Resveratrol inhibits the growth of Helicobacter pylori in vitro. Am J Gastroenterol 2000;95:1849. [CrossRef]
• Docherty JJ, Fu MM, Tsai M. Resveratrol selectively inhibits Neisseria gonorrhoeae and Neisseria meningitidis. J Antimicrob Chemother 2001;47:243–244. [CrossRef]
• Nawrocki EM, Bedell HW, Humphreys TL. Resveratrol is cidal to both classes of Haemophilus ducreyi. Int J Antimicrob Agents 2013;41:477– 479. [CrossRef]
• Paulo L, Ferreira S, Gallardo E, Queiroz JA, Domingues F. Antimicrobial activity and effects of resveratrol on human pathogenic bacteria. World J Microbiol Biotechnol 2010;26:1533–1538. [CrossRef]
• Martini S, Bonechi C, Rossi C, Figura N. Increased Susceptibility to Resveratrol of Helicobacter pylori Strains Isolated from Patients with Gastric Carcinoma. J Nat Prod 2011;74;2257–2260. [CrossRef]
• Yang T, Fang L, Sanders S, et al. Stilbenoid prenyltransferases define key steps in the diversification of peanut phytoalexins. J Biol Chem 2018;293:28–46. [CrossRef]
• Piotrowska H, Kucinska M, Murias M. Biological activity of piceatannol: Leaving the shadow of resveratrol. Mutat Res 2012;750:60–82. [CrossRef]
• Furuya T, Sai M, Kino K. Efficient monooxygenase-catalyzed piceatannol production: Application of cyclodextrins for reducing product inhibition. J Biosci Bioeng 2018;126:478–481. [CrossRef]
• Wesołowska O, Kuzdzal M, Strancar J, Michalak K. Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes. Biochim Biophys Acta 2009;1788:1851– 1860. [CrossRef]
• Kukreja A, Wadhwa N, Tiwari A. Therapeutic Role of Resveratrol and Piceatannol in Disease Prevention. J Blood Disorders Transf 2014;5:9. [CrossRef]
• Clinical and Laboratory Standards Institute, 2012. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI Document 32, M100-S22. Available at: http://zums. ac.ir/files/health/pages/ill/azmayeshghah/clsi_2013.pdf
• Kiedrowski MR, Horswill AR. New approaches for treating staphylococcal biofilm infections. Ann N Y Acad Sci 2011;1241:104– 121. [CrossRef]
• Chan MM. Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharmacol 2002;63:99–104. [CrossRef]
• Jung HJ, Hwang IA, Sung WS, et al. Fungicidal Effect of Resveratrol on Human Infectious Fungi. Arch Pharm Res 2005;28:557–560. [CrossRef]
• Ma DS, Tan LTH, Chan KG, et al. Resveratrol-Potential Antibacterial Agent against Foodborne Pathogens. Front Pharmacol 2018;9:102. [CrossRef]
• Duarte N, Kayser O, Abreu P, Ferreira MJU. Antileishmanial activity of piceatannol isolated from Euphorbia lagascae seeds. Phytother Res 2008;22:455–457. [CrossRef]
• Kedzierski L, Curtis JM, Kaminska M, Jodynis-Liebert J, Murias M. In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes. Parasitol Res 2007;102:91–97. [CrossRef]
• Mishra NC, Sharma M, Sharma A. Inhibitory effect of piceatannol, a protein tyrosine kinase inhibitor, on asexual maturation of Plasmodium falciparum. Indian J Exp Biol 1999; 37:418–420.